Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer
Caitlin Molczyk, Reegan Sturgeon, Sugandha Saxena, Esther Johnson, Rick Bhatia, Namita Bhyravbhatla, Sushil Kumar, Surinder K. Batra, Rakesh K. Singh
This study shows that inhibiting CXCR2 can enhance gemcitabine's effectiveness in pancreatic cancer by overcoming resistance in both parental and gemcitabine-resistant cells.
FASEB BioAdvances · Jan 1, 2026Peer-reviewedCancer Biology